Skip to search formSkip to main contentSkip to account menu

MK 2206

Known as: Akt inhibitor MK2206, MK-2206, MK2206 
An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Heterocyclic Compounds, 3-Ring
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Exogenous hydrogen sulfide attenuates the development of diabetic cardiomyopathy via the FoxO1 pathway
Previous studies have suggested that exogenous hydrogen sulfide can alleviate the development of diabetic cardiomyopathy (DCM) by… 
2017
2017
MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer
The present study assessed the role of metastasis-associated protein 1 (MTA1) in epithelial to mesenchymal transition (EMT) and… 
2015
2015
Maslinic acid promotes synaptogenesis and axon growth via Akt/GSK-3β activation in cerebral ischemia model.
2015
2015
Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.
524 Background: A key node of growth and survival signaling pathways is the Akt serine/threonine kinase that activates mTOR and… 
2014
2014
A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study
We report results of a phase I trial designed to estimate the maximum tolerated dose (MTD), describe dose‐limiting toxicities… 
2014
2014
Nucleolin enhances internal ribosomal entry site (IRES)-mediated translation of Sp1 in tumorigenesis.
2013
2013
AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL
The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression… 
2013
2013
Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells
2010
2010
First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation…
3009 Background: Akt mediates cell proliferation, survival, and angiogenesis and is deregulated in cancer. MK is a potent… 
2009
2009
Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor
Aberrant activation of the serine/threonine kinase Akt, a central node of the PI3K pathway, has been found in a significant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)